// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Phase IIIb CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2- advanced breast cancer (ABC): Interim results from the UK cohort

Alistair Ring - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ribociclib

Mortality rates associated with clinical and pathological characteristics of hormone receptor positive human epidermal growth factor receptor 2 negative early breast cancer: An analysis of the 2010-2016 surveillance, epidemiology, and end results data

Jacqueline Brown - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Computer extracted features of nuclear shape, orientation disorder and texture from H&E Whole slide images are associated with disease-free survival in ductal carcinoma in situ (DCIS)

Haojia Li - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)

Tor Biering-Srensen - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

omecamtiv mecarbil (IV)

Comparison of Nt-proBNP Concentrations When in or out of Heartlogic Alerts

John P. Boehmer - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Safety and Efficacy of Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure: A Systematic Review and Meta-analysis

Waqas Ullah - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

A First in Human Multi-center, Open Label, Prospective Study to Evaluate Safety, Usability and Performance of the VisONE System for Heart Failure with a Reduced Left Ventricular Ejection Fraction

John G.F. Cleland - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Congestive heart failure

N/A

Long-term Survival Benefit of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy

Jignesh Patel - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Transthyretin cardiac amyloidosis

Tafamidis meglumine

Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnea in Heart Failure Patients

Lee R. Goldberg - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Sleep apnoea

N/A

Long-term Integrated Safety of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Julian Gillmore - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Familial Amyloid Polyneuropathy

Patisiran

The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy

Margaret M. Parker - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Familial Amyloid Polyneuropathy

Methadone hydrochloride

Long-term Cardiac Remodeling and Outcomes after LVAD Discontinuation for Myocardial Recovery with Device Left In-Situ

Eleanor F. Gerhard - Heart Failure Society of America (HFSA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Nonischemic cardiomyopathy

N/A

Postoperative Critical Care Improves Mortality - Causal Inference Analysis Of A 248 Hospital Cohort

Tharusan Thevathasan - American Society of Anesthesiologists (ASA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterisation Of Reflective Capacity Of Anaesthetic Trainees In An Irish Tertiary Referral Teaching Hospital

Hassan Ahmed - American Society of Anesthesiologists (ASA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predicting Death In Emergency Laparotomy: An Uncertainty-aware Model Developed Using Data From 179 Uk Hospitals

Finneas Catling - American Society of Anesthesiologists (ASA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Neuroprotection is improved by watertightness of spina bifida repair in the fetal lamb

Luc Joyeux - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Spina bifida

N/A

Perinatal and genetic outcomes associated with no call cfDNA results in 18,496 pregnancies

Mary E. Norton - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Influence of maternal body mass index on interobserver variability of fetal biometry in late pregnancy

Juliana Gevaerd Martins - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Multicenter prospective study of SNP-based cfDNA screening for aneuploidy with genetic confirmation in 18,496 pregnancies

Pe'er Dar - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Multicenter prospective study of SNP-based cfDNA for 22q11.2 deletion in 18,289 pregnancies with genetic confirmation

Pe'er Dar - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Velocardiofacial syndrome

N/A

Copyright © 2026. QuantiNova All rights reserved